Repros gets the nod to proceed in clinical trials

• The FDA notifies Repros Therapeutics (NASDAQ:RPRX) that it may proceed with phase 1 and phase 2 studies for Proellex under separate INDs for endometriosis and uterine fibroids while remaining on partial clinical hold.
• The maximum allowed dose will be 12 mg daily.
• Consensus 2015 revenue estimate is $16.8M.
• 133 mutual funds have positions, up from 120 a year earlier.